Table 1.
Demographics stratified by mannose-binding lectin deficiency definitions
| All subjects |
MBL concentration (ng/mL)
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| ≤50 | >50 | ≤100 | >100 | ≤500 | >500 | >50 and ≤1000 | >1000 | ||
| All subjects, n (%) | 1037 (100) | 5 (0.5) | 1032 (99.5) | 20 (1.9) | 1017 (98.1) | 251 (24.2) | 786 (75.8) | 542 (52.3) | 490 (47.3) |
| Gender | |||||||||
| Female, n (% of total female) | 412 (100) | 2 (0.5) | 410 (99.5) | 10 (2.4) | 402 (97.6) | 126 (30.6) | 286 (69.4) | 239 (58.0)* | 171 (41.5)* |
| Male, n (% of total male) | 625 (100) | 3 (0.5) | 622 (99.5) | 10 (1.6) | 615 (98.4) | 125 (20.0) | 500 (80.0) | 303 (48.5) | 319 (51.0) |
| Race | |||||||||
| Caucasian, n (% total Caucasian) | 854 (100) | 3 (0.3) | 851 (99.7) | 12 (1.4) | 842 (98.6) | 194 (22.7) | 660 (77.3) | 442 (51.8) | 409 (47.9) |
| Black, n (% total black) | 136 (100) | 2 (1.5) | 134 (98.5) | 7 (5.1) | 129 (94.9) | 49 (36.0) | 87 (64.0) | 80 (58.8) | 54 (39.7) |
| Hispanic, n (% total Hispanic) | 25 (100) | 0 (0.0) | 25 (100) | 1 (4.0) | 24 (96.0) | 7 (28.0) | 18 (72.0) | 14 (56.0) | 11 (44.0) |
| Age, years (±SD) | 65.4 (8.6) | 62.2 (5.3) | 65.4 (8.6) | 64.3 (9.0) | 65.4 (8.6) | 65.6 (8.4) | 65.4 (8.6) | 65.5 (8.5) | 65.3 (8.7) |
| Post-bronchodilator FEV1, L (±SD) | 1.11 (0.51) | 1.07 (0.72) | 1.11 (0.50) | 1.10 (0.45) | 1.11 (0.51) | 1.06 (0.45) | 1.13 (0.52) | 1.09 (0.48) | 1.13 (0.54) |
| Post-bronchodilator FEV1, % predicted (±SD) | 39.5 (15.5) | 34.8 (17.1) | 39.5 (15.5) | 39.7 (13.9) | 39.5 (15.6) | 39.4 (14.6) | 39.5 (15.8) | 39.7 (15.3) | 39.4 (15.8) |
| FEV1/FVC, % (±SD) | 42.5 (12.7) | 46.4 (18.0) | 42.5 (12.7) | 47.0 (14.0) | 42.4 (12.7) | 43.2 (12.4) | 42.3 (12.8) | 42.9 (12.4) | 42.0 (12.9) |
| GOLD stage | |||||||||
| 2, n (% of total stage 2) | 266 (100) | 2 (0.8) | 264 (99.3) | 5 (1.9) | 261 (98.1) | 60 (22.6) | 206 (77.4) | 133 (50.0) | 131 (49.2) |
| 3, n (% of total stage 3) | 428 (100) | 1 (0.2) | 427 (99.8) | 10 (2.3) | 418 (97.7) | 113 (26.4) | 315 (73.6) | 241 (56.3) | 186 (43.5) |
| 4, n (% of total stage 4) | 339 (100) | 2 (0.6) | 337 (99.4) | 5 (1.5) | 334 (98.5) | 78 (23.0) | 261 (77.0) | 165 (48.7) | 172 (50.7) |
| Current smoker, n (%) | 220 (21.2) | 1 (0.5) | 219 (99.5) | 2 (0.9) | 218 (99.1) | 49 (22.3) | 171 (77.7) | 105 (47.7) | 114 (51.8) |
| Former smoker, n (%) | 816 (78.8) | 4 (0.5) | 812 (99.5) | 18 (0.2) | 798 (97.8) | 202 (24.8) | 614 (75.2) | 436 (53.4) | 376 (46.1) |
| Use of inhaled steroids, n (%) | 806 (77.7) | 4 (0.5) | 802 (99.5) | 17 (2.1) | 789 (97.9) | 207 (25.7) | 599 (74.3) | 429 (53.2) | 373 (46.3) |
| No inhaled steroids, n (%) | 231 (22.3) | 1 (0.4) | 230 (99.6) | 3 (1.3) | 228 (98.7) | 44 (19.0) | 187 (81.0) | 113 (48.9) | 117 (50.7) |
| Chronic bronchitis, n (%) | 485 (47.0) | 2 (0.4) | 483 (99.6) | 5 (1.0) | 480 (99.0) | 108 (22.3) | 377 (77.7) | 248 (51.1) | 235 (48.5) |
| No chronic bronchitis, n (%) | 546 (53.0) | 3 (0.5) | 543 (99.5) | 15 (2.7) | 531 (97.3) | 142 (26.0) | 404 (74.0) | 290 (53.1) | 253 (46.3) |
Note:
*
P < 0.05.
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; MBL, mannose-binding lectin; SD, standard deviation.